Tri-specific human immunodeficiency virus antibodies for immunotherapy
This technology is a tri-specific antibody targeting multiple epitopes of the human immunodeficiency virus (HIV) for immunotherapy against HIV infection and prevention of viral transmission.
Unmet Need: Multiple epitope specific antibody for treatment of HIV
Current methods to treat human immunodeficiency virus (HIV) require daily pills and expensive regimes for the lifetime of the patient. Alternatives in development include antibody therapy applied biannually, including monoclonal and bispecific antibodies which may also decrease the reservoir of infected T cells. However, long term HIV requires at least three different antiretroviral molecules to effectively suppress the virus and there are no HIV antibody therapies on the market.
The Technology: HIV antiretroviral therapy with long-half life to treat viral escape HIV variants
This technology describes a tri-specific HIV targeted humanized antibody. This therapeutic antibody targets three regions on the HIV viral envelope. Since HIV variants have resistance through viral escape methods, including mutations at the viral surface, multiple viral targets are needed for long-term HIV treatment. This technology targets three distinct regions on the HIV viral envelope with the same antibody formulation.
This technology has been validated in vivo with pharmacokinetic studies in mice.
Applications:
- Therapeutic for HIV treatment
- Preventative of HIV infection and transmission
- Therapeutic for prevention of viral transmission from pregnant patient to fetus
- Research tool for studying treatment of HIV variants and viral escape pathways
- Research tool for therapeutic targeting of viruses
Advantages:
- Improved potency against HIV compared to monospecific and bispecific antibody treatments
- Requires fewer therapeutic doses than current daily therapeutics
- Compatible in combination with current therapeutics
- Single, combination treatment targeting three separate epitopes in one antibody formulation
- May reduce viral reservoir in patient T cells to reduce overall patient viral load rather than eliminate only circulating virus
Lead Inventor:
Patent Information:
Patent Issued (US 10,654,943)
Related Publications:
Tech Ventures Reference:
IR CU22364
Licensing Contact: Kristin Neuman